Cryoport (NasdaqCM:CYRX) Q3 2025 Earnings Call November 04, 2025 05:00 PM ET Speaker4Good afternoon and welcome to Cryoport's Third Quarter 2025 earnings conference call. All participants will start in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. As a reminder, this call is being recorded. I will now turn the call over to your host, Todd Fromer, from KC ...

TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program. The federally-supported program, launched through a grant from the U.S. Economic Development Administration, helps early-stage biotechnology companies accelerate the translation of regenerative innov ...

Conference call and webcast to be held at 4:30 PM ETPOMPANO BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the quarter fro ...

Hemostemix's Boots on the Ground in Florida October UpdateOctober 30, 2025 11:29 AM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiom ...

公司战略与项目启动 - 临床阶段再生医学公司Creative Medical Technology Holdings Inc (NASDAQ: CELZ) 正式启动其子公司BioDefense Inc的退伍军人计划，旨在对抗美国军人因有毒燃烧坑暴露造成的长期影响，据信这是首个全国性此类项目 [1] - 该计划旨在通过将公司定位为国家医疗准备和退伍军人健康安全的基石，在美国生物防御基础设施中建立关键角色 [2] - 该计划被描述为不仅是一项科学计划，更是一项国家要务，旨在将生物技术、人工智能和爱国主义融合为一项变革性使命 [4][7] 技术平台与合作细节 - 项目将利用公司专有的诱导多能干细胞（iPSC）和再生修复技术及算法，结合人工智能分析，以识别、模拟和逆转有毒暴露相关疾病通路 [2] - 公司选择与Greenstone Biosciences Inc作为独家人工智能和iPSC开发合作伙伴，后者由斯坦福大学Joseph C Wu博士共同创立，并与NVIDIA有合作关系 [4] - 在此合作下，Greenstone将部署先进的分子测序、蛋白质组学分析和机器学习算法，分析暴露于燃烧坑的军人的细胞数据，以加速创建预测性暴露模型和精准再生疗法 [5] 项目目标与能力建设 - BioDefense Inc正在主导燃烧坑暴露分子特征分析项目，旨在创建美国历史上最大的退伍军人有毒暴露分子水平数据库之一，作为精准再生对策的基础 [3] - 该国家项目将提供关键的数据基础设施，以开发可部署于军事和民用人群的预测性、先发性疾病建模系统 [6] - 项目具体目标包括解码有毒暴露相关损伤的基因组和蛋白质组结构，利用公司专利细胞平台开发基于iPSC的再生修复模型，以及验证用于暴露分类和精准干预的下一代人工智能/机器学习生物防御算法 [9]

公司合并交易进展 - 与Revive Regenerative Inc的合并交易原定截止日期为2025年10月30日，但投资银行顾问表示需要额外约30天来完成流程 [1] - 合并交易的完成条件包括将公司所有债务转换为股权，目前正与财务顾问公司积极同所有债权人及债务人就此进行谈判 [1] - 除初始的50万美元过桥融资外，公司正根据合并协议与各方投资者进行额外的300万美元融资 [1] - 双方已完成尽职调查，并对两家公司的整合感到非常满意，均希望在上述债务问题得到满意解决后尽快完成交易 [1] - 关于债务转换的更明确更新预计在未来7至10天内公布 [1] 产品线与业务发展 - 公司正在敲定与一家以色列生物制造公司的合作伙伴关系，未来将更新面向消费者的生物化妆品Cielo Skin Care的状况 [1] - 公司正在与一家远程医疗GLP-1肽公司谈判，以期获得全套GLP-1产品及各种肽产品，与公司现有的生物制剂产品线结合销售 [1] - 首席执行官认为，合并后的新公司将结合Revive Regenerative的激光和能量设备、基于外泌体的生物美学产品线，以及潜在的新GLP-1减肥产品和额外肽产品线，成为全球首批完全整合的此类公司之一 [3] - 此举预计将显著提升公司的顶线收入并创造可观的底线税息折旧及摊销前利润 [3] 公司业务概况 - Apollo Biowellness Inc及其子公司Evolutionary Biologics Inc致力于发现、开发和销售旨在改善人类的产品，并定位为美国国立卫生研究院定义的再生医学领域的领导者 [4] - 公司当前努力重点在于销售已获许可的、专利待决的天然干细胞动员剂，该制剂能增强个体从骨髓中动员自身成体干细胞的能力 [4][5] - 公司还根据一项专利待决的申请获得许可，销售一种双重作用的纯天然饮食辅助品，旨在通过向大脑和胃传递正常身体信号来帮助控制饥饿感 [5] - 产品正为消费者市场和专业市场开发 [5]

业绩总结 - United Therapeutics在2025年第三季度的总收入为8亿美元，同比增长7%[30] - Tyvaso DPI和雾化Tyvaso的收入为4.78亿美元，同比增长10%[30] - Orenitram的收入为1.31亿美元，同比增长16%[30] - Unituxin的收入为4800万美元，同比增长22%[30] - Remodulin的收入为1.26亿美元，同比下降2%[30] - 过去12个月的运营现金流为16亿美元[31] - 现金、现金等价物和可市场投资总额为43亿美元[31] 用户数据 - Tyvaso在美国的收入同比增长12%至4.7亿美元[66] - Remodulin季度收入为1.26亿美元，同比下降2%[75] - U.S. Remodulin收入同比下降4%，为1.11亿美元[75] - Unituxin季度收入为4800万美元，同比下降22%[82] - U.S. Unituxin收入同比下降19%，为4700万美元[82] - Unituxin在美国是高风险神经母细胞瘤的最常用抗体疗法[84] 未来展望 - TETON-2研究的主要终点在52周时达成统计显著性[37] - Ralinepag的ADVANCE OUTCOMES研究已完全招募728名患者，预计2026年上半年将公布数据[47] - 从2023年第三季度到2025年第三季度，Remodulin的美国复合年增长率为0%[77] - 从2020年第三季度到2025年第三季度，整体收入的复合年增长率为12%[73] 新产品和新技术研发 - RemunityPRO下一代皮下泵最近推出[79] - 创纪录的患者发货量，连续第15个季度实现同比收入增长[74]

POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the Audit Committee of its Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company's independent registered public accounting firm, and it has ended its engagement with its prior registered independent publ ...

Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year ...

Accessibility StatementSkip Navigation -- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into N ...